PreludeDx Announces Groundbreaking Study Results on HER2-Positive DCIS Patients

Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, today announced the results of a cutting-edge study in Clinical Breast Cancer. The study marks a significant advancement in personalized treatment for DCIS patients.

Prelude is a UCSF start-up from the lab of Thea Tlsty, PhD. Congratulations Professor Tlsty!